© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of vismodegib picks up in the 2000s, years after researchers learned that certain genetic mutations drive cancer by unlocking pathways that create uncontrolled cell growth. Scientists spent long nights digging through signal transduction pathways. The Hedgehog signaling system, in particular, showed a deep link with basal cell carcinoma (BCC), the most common human cancer. Pharmaceutical innovators, realizing that most standard therapies often leave patients with incomplete treatment options, zeroed in on small molecules that block this pathway. Vismodegib, a first-in-class smoothened (SMO) antagonist, moved from lab benches into clinical trials with speed not many drug candidates enjoy. In 2012, after a string of studies proved it significantly shrank advanced BCC tumors in patients who had no other choices left, the FDA approved vismodegib. There’s a reason this approval marked a major moment—not just for BCC care, but for targeted therapies as a whole.
Vismodegib comes as an oral capsule, usually administered once a day. Its appearance, specific dosage recommendations, and navigational rules surprise newcomers who expect traditional chemotherapy. While chemotherapy often brings up images of hair loss and severe illness, vismodegib works differently by interrupting the Hedgehog pathway, minimizing the damage to non-cancerous tissue. Commercially, brands like Erivedge carry vismodegib into cancer clinics around the world. This drug has been kept mostly within the boundaries of oncology departments, moving through strict distribution channels that focus on safety and insurance controls. Many hospitals reserve it for patients facing advanced basal cell skin cancers—especially those inoperable by surgery or unresponsive to radiation.
Vismodegib carries a molecular formula of C19H14Cl2N2O3S and a molecular weight close to 421.3 g/mol. The substance itself typically appears as a white to off-white crystalline powder. This may sound academic, but physical properties actually affect shelf stability, capsule formulation, and patient convenience. Its water solubility hovers at less than 0.1 mg/mL at 25°C, hinting at some challenges for oral bioavailability. Chemists working with this compound use its melting point (nearly 192–194°C) and logP value (around 2.7) to design proper delivery systems and predict its ability to cross cell membranes. These factors play a central part in making sure each capsule delivers consistent, effective treatment with minimal waste.
Healthcare professionals will find vismodegib in capsules, most commonly at a 150 mg dose. Manufacturers stick to rigorous labeling: each bottle carries information about storage, expiration, and detailed usage instructions. US Pharmacopeia (USP) standards mean that each package must pass identity, purity, potency, and stability tests. Labels highlight contraindications—pregnant women face serious teratogenic risk from vismodegib, for instance—along with comprehensive side effect lists and contact information for reporting adverse events. These technical specs keep patient safety front-and-center and let hospitals craft their own protocols for dispensing high-risk oncology medications, often including patient education and close monitoring.
The path to pure vismodegib involves several key synthetic steps. Early-stage chemical syntheses use a combination of aromatic substitution and heterocycle formation. The main process involves reacting a substituted benzoic acid with an aryl chloride, followed by a series of condensation reactions and protective group strategies. The route needs to prevent structural isomerization or loss of critical groups, which can lead to decreased potency or batch rejection. Production teams optimize each reaction step for safety, yield, and ease of purification so that ultimately, every batch meets pharmaceutical-grade requirements. Industrial manufacturers automate large parts of the process and invest in solvent recycling to limit environmental impact.
Vismodegib’s structure, packed with aromatic rings and a thioamide group, presents chemists with both hurdles and opportunities during synthesis. Functionalization of these groups allows for possible development of analogs with improved pharmacokinetic or pharmacodynamic properties. Modifying portions of the molecule, including N-alkylation or oxidation procedures, has yielded experimental derivatives with altered activity profiles. These modifications drive much of the ongoing medicinal chemistry work, as researchers hope to create next-generation Hedgehog pathway inhibitors that split the difference between maximum potency and minimal side effects. Extension of these methods holds value for drug designers trying to tackle resistance mechanisms seen in long-term cancer patients.
Vismodegib passes through various technical and commercial aliases. In the lab, it often gets called by its chemical description: 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide. Pharmacies know it as Erivedge, the approved and marketed form. Other designations include GDC-0449 or RG3616, carried over from the early phases of research and clinical development. No matter the name, what matters most to doctors and patients is that these synonyms all refer to a drug that targets advanced basal cell carcinoma with a specificity that earlier treatments could not match.
Vismodegib’s safety profile comes with warnings that healthcare providers stress heavily during counseling. The teratogenic risk ranks among the highest, and prescribers provide clear documentation about contraceptive rules for both male and female patients—exposure during pregnancy can lead to severe fetal abnormalities. The side-effect profile includes muscle spasms, hair loss, weight loss, fatigue, and taste changes, all documented in clinical trials and post-marketing surveillance. Hospitals storing and handling vismodegib operate under strict protocols, using secure storage, regular inventory checks, and dedicated staff training. Pharmacovigilance measures, enforced by regulatory agencies, drive ongoing safety evaluations. Rigorous systems for tracking adverse events, lot consistency, and patient support initiatives are mainstays to avoid preventable errors or misuse.
Doctors reach for vismodegib when facing locally advanced or metastatic basal cell carcinoma, especially in patients with limited options. For individuals whose tumors resist surgery or radiation—or in cases where removing tissue would leave disabling scars or dysfunction—vismodegib steps in as a viable, oral alternative. Some off-label experimentation includes consideration for medulloblastoma and other solid tumors with evidence of Hedgehog pathway activation, but so far, the strongest data exists for skin cancer. The utility of vismodegib underscores the movement toward personalized cancer therapy, where genetic and molecular profiling of tumors matters more than their organ of origin.
Much of current R&D centers on understanding why some tumors eventually develop resistance to vismodegib. Teams at academic and industry labs sequence cancer recurrence samples, pinpointing genetic mutations within the Smoothened (SMO) gene or downstream effectors that bypass the drug’s blockade. Scientists also test vismodegib in combination with other agents, such as immune checkpoint inhibitors or DNA-damaging drugs, searching for powerful synergies. The chemistry side continues to chase analog development, trying to sidestep the pharmacokinetic and tolerability limitations of the current molecule. Each success and setback adds detail to the growing map of how Hedgehog pathway inhibition interacts with the broader world of cancer biology.
Safety studies for vismodegib have been both extensive and sobering. Clinical trials showed that alongside manageable side effects in many patients, there are serious risks: birth defects, severe muscle pain, and rare but dangerous liver problems. Animal tests confirmed teratogenicity so striking that regulators called for boxed warnings. The chronic side effects, such as muscle cramps and hair loss, wear down patient morale and affect ongoing compliance. Toxicologists keep a close watch on long-term exposure, since patients with inoperable BCC sometimes take the drug for years. Monitoring and clear communication help troubleshoot problems early and steer doctors toward alternative regimens if side effects grow too much to bear.
Vismodegib broke ground as a new way to treat basal cell carcinoma, but its story isn’t close to over. Researchers chase next-generation Hedgehog inhibitors with designs that overcome resistance, reach new tumor types, and bring down the side-effect burden. Precision medicine pushes physicians to dig deeper into patient genetics, picking out subgroups most likely to benefit. The experience with vismodegib shapes ongoing conversations around targeted therapy, access, and drug pricing. As regulatory authorities consider broadening approval to pediatric populations and new cancers driven by aberrant Hedgehog signaling, this molecule’s influence stretches beyond dermatology into the broader world of oncology. With every study, it opens fresh questions—and opportunities—for cancer care in the years ahead.
Cancer has always been a word that carries weight, especially for families who have seen its effects up close. Treatments keep changing, and one of those changes includes medicines designed for rare cases that didn’t have many options. Vismodegib didn’t pop up overnight. Scientists saw that standard chemotherapy wasn’t doing the job for certain skin cancers. Now, if you talk with dermatologists or oncologists, you’ll hear vismodegib come up in conversations about tackling tough basal cell carcinoma.
Most skin cancers get caught early. Their growth tends to stay local, and a surgeon can often clear things out quickly. Basal cell carcinoma shows up in stubborn ways for some people, growing more than anyone expected, spreading deeper, or even traveling to other parts of the body. That's rare, but it’s devastating for patients who’ve already endured countless treatments. Vismodegib gives hope here. It’s built for adults whose basal cell cancer has spread or can’t be cut out or treated with radiation anymore.
The real trick behind vismodegib sits in how it presses the brakes on a pathway known as “Hedgehog.” That name stuck from early genetic studies. Basal cell carcinomas often come from glitches in this pathway. Vismodegib blocks signals that help these cancer cells grow and multiply. Without those messages, the cancer gets weaker. Clinical studies put numbers behind this approach. For people with locally advanced disease, close to half saw their tumors shrink. For those with spread to other organs, about a third responded. It isn’t magic, and side effects can be tough. Muscle cramps, hair loss, tiredness, and taste changes show up pretty often.
Doctors talk openly about risks and benefits with their patients. Soft tissue and bone involvement complicate surgery, and in some spots, like around the eyes or ears, it’s hard to get clear margins. If there’s no way to cut out the cancer or target it with a beam, vismodegib comes up as an option. For many, it feels like a last hope—no longer “just skin cancer” but a real threat to health and to quality of life.
Access remains a hurdle. Vismodegib isn’t cheap, and insurance approval sometimes becomes a battle. Not every patient tolerates the side effects, especially older adults with other conditions. Monitoring and regular check-ins matter. For women, strict birth control is a must during treatment, since birth defects are a serious risk. There’s pressure on scientists to keep looking for better tools or combination treatments so more people benefit. Evidence from the last ten years shows progress, but the work continues.
Patients and families often share stories of finding new treatments right when they need them most. Vismodegib changed that story for some, letting doctors offer a way forward where the path before seemed blocked. Real relief comes when treatments like this one get safer, more effective, and more available, so more people get a fighting chance.
Vismodegib is a medication doctors turn to for treating certain skin cancers, especially basal cell carcinoma that doesn't respond to surgery or radiation. From the first dose, some people notice changes in their body. Hair starts to thin or fall out. Taste buds may stop working the same—the flavor of foods changes, or meals lose appeal altogether. These effects hit home fast, making everyday life different.
More than a few folks experience loss of appetite. Losing interest in eating may lead to weight loss over the weeks. I've seen patients complain about muscle cramps that don't let up after activity. That nagging pain interrupts sleep, slows down walking, and makes chores tougher. The muscle spasms come from the way Vismodegib interrupts pathways needed for normal cell work, not just those fueling cancer growth.
Stomach problems are part and parcel of many cancer therapies, and Vismodegib fits that pattern. Nausea worsens with each meal for some patients. Constipation lingers, sometimes followed by diarrhea that shows up without warning. Patients tend to need gentle, regular meals and lots of water to keep things moving. For those over 60, keeping up with hydration becomes even more pressing when digestive issues come into play.
Vismodegib brings a bone-deep tiredness that can catch up to cancer survivors used to being fighters. One day you’re on your walk, the next you nap twice before lunch. This level of fatigue chips away at independence since it trails after activities all day. The struggle is not just physical, either. Many folks share that the tiredness and constant body changes make it tough to stay upbeat—losing hair, dealing with cramps, and never feeling quite like yourself starts to wear on anyone.
Elderly patients feel the brunt of these symptoms more than younger folks. Muscle wasting links directly to physical weakness, poor appetite, and risk of falls. Those who already deal with chronic health issues or malnutrition need extra watching. Doctors look beyond numbers on blood tests and ask about daily life—how much pain, how many skipped meals, and how much walking still gets done.
Fact-based advice makes a difference. Matching high-calorie, easy-to-swallow foods with gentle exercise like stretching can slow muscle loss. Hair thinning is tough, but covering up with soft caps or scarves and seeking out cancer support groups lessens the sting. Oral care matters, too. Using mouth rinses and flavor enhancers sometimes bring back the pleasure of food. For muscle cramps, magnesium-rich foods and warm baths become part of the daily routine for many.
Doctors and patients need honest conversations about these side effects. Unplanned weight loss or muscle wasting could mean needing to pause or adjust the dose. Recognizing early signs of dehydration, feeding problems, or severe tiredness can stop trouble before it gets worse. I’ve seen people regain control when they track symptoms and reach out to their care team quickly. Keeping open lines with nurses, nutritionists, and loved ones helps everyone handle what Vismodegib brings.
Dealing with advanced basal cell carcinoma feels daunting enough before anyone even opens a pill bottle. Vismodegib, used for this type of skin cancer, comes as a prescription pill you swallow. The pill is meant for daily use, and it’s typically taken around the same time every day. The instructions say not to open, crush, or chew it. Swallowing whole is key. Some folks might find that challenging, but doctors and pharmacists can usually offer smart suggestions for handling large or tough-to-swallow tablets.
You don’t have to line up your meals or snacks with your dose. The body absorbs vismodegib just fine with or without food. This might sound like a small detail, but it takes pressure off, especially if a patient isn’t feeling hungry or can’t keep regular meal times due to treatment side effects. I’ve had family members on tough regimens, and any bit of flexibility around meals and pills made a difference for them.
Cancer regimens can wear folks down over time. Daily medication routines demand real consistency, and vismodegib isn’t any different. Missing doses can reduce effect and open the door for cancer cells to adapt or return. On top of that, the pill can bring unwelcome side effects—muscle spasms, taste changes, hair loss, and fatigue. In the clinical trial ERIVANCE BCC, up to a third of patients had to pause or lower the dose due to these problems. That’s a big number and proves this medicine isn’t just another pill.
Taking vismodegib safely depends on regular touchpoints with the care team. Doctors often run blood tests to keep an eye on liver function, kidney health, and how the body’s handling the drug. Patients share updates on symptoms during these check-ins, so tweaks can be made early—long before the problem grows. Staying honest about missed doses or side effects makes a real difference. A pharmacist or nurse helping you track your meds on a calendar or app removes some of the confusion. Support isn’t “extra.” It shapes outcomes.
Adults of childbearing potential (and their partners) have to follow strict safety steps, since vismodegib can cause birth defects. This means reliable birth control while taking vismodegib and for months after stopping it. Skipping these safety steps isn’t just risky—it endangers future pregnancies and puts others at indirect risk if pills get shared or disposed of carelessly. The patient guides and warnings push this hard for a reason.
Doctors, nurses, and pharmacists all stress communication. Scheduling reminders, using weekly pill boxes, and looping in family can keep medication on track. Clinics working with social workers and navigators help families find transportation or financial assistance for prescriptions. The science points out that high-touch support and check-ins mean patients stay on therapy longer, have fewer bad reactions, and need fewer emergency visits.
Vismodegib isn’t a magic bullet but offers hope for cancers that resist surgery and radiation. Dosing looks straightforward on paper—it’s the daily grind and life hurdles where things get complicated. The more folks share honestly with their care teams, the more likely treatment can work as planned.
Vismodegib works as a treatment for basal cell carcinoma, a form of skin cancer that can grow deep and stubborn. It blocks a growth pathway in cancer cells, slowing the disease. For folks with tough tumors that surgery or radiation won’t touch, this drug can feel like a ray of hope. Still, hope shouldn’t blind anyone to risks.
Pregnancy and Vismodegib do not mix. The drug causes severe birth defects— its label outlines this in detail. Scientists first saw these effects in animal studies. Pregnant people, and those planning a pregnancy soon, run a real risk. Doctors stress using two forms of birth control, not just one. Even men taking Vismodegib must play it safe: the drug passes through semen. Anyone who’s expecting a child, or even trying, should steer clear.
Vismodegib interrupts bone growth in children and teens. Reports show bone problems, including fusions and side effects that may never go away. Kids can develop skeleton changes that adults never face, so regulators say “no” when folks under 18 ask about this treatment. Even if a rare young person faces dangerous tumors, this risk tips the balance against using Vismodegib.
Allergies to medicine don’t show mercy. If someone reacts badly to any part of a Vismodegib capsule—say, gets swelling, breathing trouble, rash—that risk outweighs any benefit from continued use. Urgent care comes first. Some allergic reactions can move fast and put life on the line.
Liver and kidney problems make many medicines more dangerous. Vismodegib hasn’t been well-studied in folks with serious liver or kidney issues. If someone’s organs already struggle, the drug’s effects can stack up in their system. Some cancer patients already live with other chronic diseases, and introducing another risk needs careful weighing. Oncologists often work with a whole team to dig through these details.
Some drugs mess with how Vismodegib moves through the body. For example, medicines that block certain stomach acids could change how much Vismodegib the gut absorbs. Some antibiotics, antidepressants, or epilepsy treatments can ramp up or slow down the drug’s clearing from the body. Regular communication between all doctors treating a patient—sometimes that’s what makes Vismodegib safer or rules it out.
I’ve seen doctors emphasize trust and clear talk when faced with these cancer treatments. Honest discussion about pregnancy, about other meds, about the risk of bone changes—these protect patients better than any single prescription. Some folks feel embarrassed to discuss all health details or might think “it doesn’t matter.” It does. A team that listens and a patient who shares openly—that keeps dangerous surprises out of the picture. Before anyone takes Vismodegib, they deserve a full conversation, not just a hurried moment at a busy clinic.
Most people searching for guidance on Vismodegib just want to help someone they love—or maybe they face the treatment themselves. Respect for the warning signs, not just blind faith in new drugs, supports families in tough times. Open questions, honest talk, and shared decision-making matter more than chasing quick cures. Taking the time to consider who should—or should not—take this medicine, saves hardship later on.
Vismodegib steps up as a game-changer for treating basal cell carcinoma after surgery or radiation no longer fit the bill. This medication blocks a specific Hedgehog signaling pathway, slowing cancer growth. Physicians choose it when standard treatments hit a dead end. Most patients receive a 150 mg daily dose, often for months, which puts it in territory where other meds might cross its path.
Doctors often see patients juggling several prescriptions. Chronic conditions, cancer recovery, and aging push drug counts higher. Vismodegib enters the mix with a well-defined risk: interactions with other medications. I’ve talked with pharmacists who cringe when oncology patients add another pill to their routine, knowing the domino effect that can follow.
Vismodegib gets broken down in the liver, mainly through the CYP450 enzyme system. Out of habit, most patients don’t question how their prescriptions change how the body processes a new drug. Vismodegib’s interaction list grows longer because the same enzymes metabolize everything from antifungals to seizure medicines.
The story doesn’t stop there. If someone starts taking a potent inhibitor or inducer—think ketoconazole or phenytoin—it can throw off Vismodegib levels either by raising side effect risk or cutting down how much makes it to the bloodstream. Some patients I’ve known have needed dose changes, extra side effect monitoring, or more frequent bloodwork because of these issues.
Cycling in anti-seizure drugs, antibiotics, or certain antidepressants can matter greatly. Even products most people don’t think much about, like over-the-counter antacids, may get flagged by cancer care teams. Grapefruit juice often lands on the “no-go” list.
Some blood thinners and heart medications complicate this story further. Elderly patients, who often take several cardiac or diabetic pills, are especially vulnerable. Once, I watched a patient face a weeks-long delay after starting Vismodegib, all because they had to cycle off another medication—and coordinate it with multiple specialists.
A single overlooked drug interaction can cause significant trouble, such as dangerous side effects like severe muscle spasms, taste changes, or kidney issues. Safety checks often slide as cancer patients focus on bigger, scarier problems. People juggling several providers end up at risk because communication gaps appear, making teamwork between oncologists and primary care doctors even more essential.
I remember families frustrated by endless phone calls between doctor offices. Better information sharing and communication platforms might help close those gaps, but old-fashioned medication lists and honest check-ins at every visit build safety nets right now. Pharmacists offer expertise in flagging risks before harm happens.
Encouraging patients to keep a wallet card listing all their meds, including herbal products, can cut confusion. Oncologists can review all prescriptions more often, especially during transitions. Digital prescribing platforms can run real-time checks instead of relying on human memory.
At home, patients need to speak up about new symptoms—no matter how small. Fatigue, cramps, or even nausea tell a story worthy of attention. Open conversations give everyone on the care team a shot at catching early warning signs before they snowball.
Patient support lines, clinical pharmacists, and specialized oncology nurses all help untangle these webs. Cancer centers often offer medication reviews and education about interaction risks. Tapping into evidence-based resources like FDA labeling and up-to-date drug databases gives both patients and providers an edge in safer long-term care.
| Names | |
| Preferred IUPAC name | 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide |
| Other names |
GDC-0449 Erivedge |
| Pronunciation | /vɪzˈmoʊdədʒɪb/ |
| Identifiers | |
| CAS Number | 956104-40-8 |
| Beilstein Reference | 5360623 |
| ChEBI | CHEBI:685500 |
| ChEMBL | CHEMBL1259417 |
| ChemSpider | 21592540 |
| DrugBank | DB08865 |
| ECHA InfoCard | 03f358e8-dd70-43fd-b6b8-890786e9e66d |
| EC Number | EC number: 695-882-9 |
| Gmelin Reference | 1328877 |
| KEGG | D09712 |
| MeSH | D056928 |
| PubChem CID | 24776440 |
| RTECS number | VX8L5718PL |
| UNII | B935MFI672 |
| UN number | UN3249 |
| Properties | |
| Chemical formula | C19H14Cl2N2O3S |
| Molar mass | 421.268 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.24 g/cm³ |
| Solubility in water | Sparingly soluble |
| log P | 2.654 |
| Vapor pressure | 1.74E-14 mmHg |
| Acidity (pKa) | 4.7 |
| Basicity (pKb) | pKb = 11.71 |
| Magnetic susceptibility (χ) | -80.8×10^-6 cm³/mol |
| Refractive index (nD) | 1.581 |
| Dipole moment | 4.22 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 322.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -412.7 kJ/mol |
| Pharmacology | |
| ATC code | L01XX43 |
| Hazards | |
| Main hazards | May cause birth defects, embryo-fetal death, and is harmful if swallowed; toxic to reproduction. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Product class chemical", "Oral use", "Pregnancy warning", "Specialised distribution |
| Signal word | Warning |
| Hazard statements | H351: Suspected of causing cancer. |
| Precautionary statements | P201, P202, P264, P270, P273, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >2000 mg/kg (rat, oral) |
| NIOSH | NA849 |
| PEL (Permissible) | PEL: Not Established |
| REL (Recommended) | 150 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Sonidegib Glasdegib Cyclopamine Itraconazole |
